Eleison Pharmaceuticals LLC moved lead compound glufosfamide into a Phase III study in second-line pancreatic cancer, seeking to achieve success in a drug that was a near-miss in previous hands. The pivotal study is assessing whether glufosfamide improves survival compared to bolus 5-FU in patients with metastatic pancreatic cancer who progressed or failed therapy on a gemcitabine-based regimen.